SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 226 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,192,580 | -12.8% | 79,528 | -4.9% | 0.00% | 0.0% |
| Q2 2023 | $2,513,189 | -1.7% | 83,606 | -81.7% | 0.00% | 0.0% |
| Q1 2023 | $2,556,748 | -17.2% | 456,415 | +427.0% | 0.00% | -50.0% |
| Q4 2022 | $3,089,334 | +15.7% | 86,609 | +9.8% | 0.00% | 0.0% |
| Q3 2022 | $2,671,000 | +27.2% | 78,904 | +8.7% | 0.00% | +100.0% |
| Q2 2022 | $2,100,000 | -9.3% | 72,620 | +1.4% | 0.00% | 0.0% |
| Q1 2022 | $2,316,000 | +16.3% | 71,644 | +4.9% | 0.00% | 0.0% |
| Q4 2021 | $1,992,000 | +36.2% | 68,329 | +24.5% | 0.00% | 0.0% |
| Q3 2021 | $1,463,000 | -2.6% | 54,873 | +12.5% | 0.00% | 0.0% |
| Q2 2021 | $1,502,000 | +47.1% | 48,774 | +25.1% | 0.00% | 0.0% |
| Q1 2021 | $1,021,000 | +192.6% | 38,996 | +181.5% | 0.00% | – |
| Q4 2020 | $349,000 | +71.1% | 13,853 | +41.6% | 0.00% | – |
| Q3 2020 | $204,000 | -18.4% | 9,782 | -7.0% | 0.00% | – |
| Q2 2020 | $250,000 | +25.0% | 10,523 | -5.2% | 0.00% | – |
| Q1 2020 | $200,000 | -48.3% | 11,096 | -32.0% | 0.00% | – |
| Q4 2019 | $387,000 | -48.3% | 16,326 | -40.1% | 0.00% | -100.0% |
| Q3 2019 | $748,000 | -40.7% | 27,234 | -28.5% | 0.00% | -50.0% |
| Q2 2019 | $1,261,000 | -6.9% | 38,102 | -1.4% | 0.00% | 0.0% |
| Q1 2019 | $1,354,000 | +8.1% | 38,644 | +2.4% | 0.00% | 0.0% |
| Q4 2018 | $1,253,000 | +35.9% | 37,724 | +144.9% | 0.00% | 0.0% |
| Q2 2018 | $922,000 | +24.1% | 15,406 | -5.0% | 0.00% | 0.0% |
| Q1 2018 | $743,000 | -72.8% | 16,212 | -76.4% | 0.00% | -66.7% |
| Q4 2017 | $2,734,000 | +2.6% | 68,599 | +2.9% | 0.01% | 0.0% |
| Q3 2017 | $2,666,000 | -12.3% | 66,635 | -5.6% | 0.01% | -25.0% |
| Q2 2017 | $3,040,000 | +273.9% | 70,577 | +171.3% | 0.01% | +166.7% |
| Q1 2017 | $813,000 | +19.9% | 26,011 | -3.2% | 0.00% | +50.0% |
| Q4 2016 | $678,000 | -6.2% | 26,876 | -8.0% | 0.00% | -33.3% |
| Q3 2016 | $723,000 | -5.9% | 29,227 | -22.4% | 0.00% | 0.0% |
| Q2 2016 | $768,000 | +27.8% | 37,681 | -4.4% | 0.00% | 0.0% |
| Q1 2016 | $601,000 | +111.6% | 39,418 | +86.8% | 0.00% | +200.0% |
| Q4 2015 | $284,000 | +6.4% | 21,098 | +11.0% | 0.00% | 0.0% |
| Q3 2015 | $267,000 | +32.8% | 19,014 | +60.4% | 0.00% | 0.0% |
| Q2 2015 | $201,000 | – | 11,856 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |